Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc Announces Delay In Leep Drug Approval-AP


Sunday, 30 Jun 2013 08:00pm EDT 

The Associated Press reported that he Food and Drug Administration says it won't approve high doses of Merck & Co Inc's experimental insomnia drug, suvorexant, because of safety concerns. It could approve lower doses than Merck wanted, but new studies will be needed. Suvorexant would be first in a new class of sleep medicines that block chemical messengers in the brain that help keep people awake. But it can cause daytime drowsiness, trouble with driving and suicidal thinking, and it can interact with other drugs. 

Company Quote

57.63
0.83 +1.46%
17 Dec 2014